Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study.
about
Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles.Effects of spray drying process parameters on the solubility behavior and physical stability of solid dispersions prepared using a laboratory-scale spray dryer.Amorphous solid dispersions: a robust platform to address bioavailability challenges.Understanding pharmaceutical polymorphic transformations II: crystallization variables and influence on dosage forms.Characterization and Stability of Tanshinone IIA Solid Dispersions with HydroxyapatiteIn vitro characterization of a novel polymeric system for preparation of amorphous solid drug dispersionsRole of Self-Association and Supersaturation in Oral Absorption of a Poorly Soluble Weakly Basic Drug.Hot melt extrusion as an approach to improve solubility, permeability and oral absorption of a psychoactive natural product, piperineApplication of dissolution/permeation system for evaluation of formulation effect on oral absorption of poorly water-soluble drugs in drug development.Effect of aminoalkyl methacrylate copolymer E/HCl on in vivo absorption of poorly water-soluble drug.Design of experiments utilization to map the processing capabilities of a micro-spray dryer: particle design and throughput optimization in support of drug discovery.Evaluation of crystallization behavior on the surface of nifedipine solid dispersion powder using inverse gas chromatography.Sustained release ivermectin-loaded solid lipid dispersion for subcutaneous delivery: in vitro and in vivo evaluation.
P2860
Q33986082-A5FA19CA-626C-4214-9CC2-903B3EF58B96Q34293944-21FF602F-62F5-4301-A402-2D1B5C1FF679Q38358879-8746F43B-ECA6-4694-9AD4-A5A2A667ADC4Q38543393-0026E417-F4DA-4C60-813F-B2E518DACFE1Q38624135-AFCADAC7-33A6-4F20-9915-81D04FBB07CDQ41150354-699D10ED-4C9F-4826-B2BA-AB67F9529A38Q41339313-09B324C0-CB9B-4181-9A59-1E5108FF591BQ42433654-DB5423FD-085B-4A91-8283-3C86F13C9686Q42498380-E07182F8-AB3A-4BCC-ADF1-C7A96F3D26EDQ44646551-6841293D-4DF7-4D5B-BC73-9FB1563C1238Q45092890-9E923EAB-802D-49D2-A43A-398D1794C017Q45777414-96BBB5EE-9BE4-4213-AECC-B8B0EB13BE9DQ52864303-23047095-6E18-48F2-AA1A-1B9D67E22E6D
P2860
Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Enhanced bioavailability of a ...... ersion approach: a case study.
@ast
Enhanced bioavailability of a ...... ersion approach: a case study.
@en
type
label
Enhanced bioavailability of a ...... ersion approach: a case study.
@ast
Enhanced bioavailability of a ...... ersion approach: a case study.
@en
prefLabel
Enhanced bioavailability of a ...... ersion approach: a case study.
@ast
Enhanced bioavailability of a ...... ersion approach: a case study.
@en
P2093
P356
P1476
Enhanced bioavailability of a ...... ersion approach: a case study.
@en
P2093
Alana Ali-Reynolds
Anna Akrami
Chandra Ma
Michael Kennedy
Nidhi Mahajan
Sekhar Surapaneni
P304
P356
10.1021/MP800061R
P407
P577
2008-11-01T00:00:00Z